Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics. - 1 - Full Text View

Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics. - 1

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) Johns Hopkins University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00033020

Purpose

The purpose of this study is to test the utilization of incentive values (considerably lower than those typically used in research clinics) to motivate clients to attend treatment and initiate and sustain abstinence.

Condition	Intervention	Phase
Substance-Related Disorders	Behavioral: Behavior Therapy	Phase III

Drug Information available for:

Methadone Methadone hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized

Official Title:	Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

ASI
Opioid and cocaine use
AIDS risk behavior

Estimated Enrollment:	390
Study Start Date:	April 2001
Study Completion Date:	February 2003
Primary Completion Date:	February 2003 (Final data collection date for primary outcome measure)

Detailed Description:

The purpose of the proposed research is to implement and systematically evaluate, in community treatment settings, motivational incentive procedures that have been well researched and have proven efficacious in a variety of treatment research clinics. The study will determine if motivational incentives along with standard care therapy is more effective than standard therapy alone for the treatment of patients using cocaine or methamphetamine and entering a substance abuse treatment program.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Recent admission to an opioid substitution (methadone maintenance) CTP. Completed at least 4 weeks of maintenance at time of study entry
Evidence of cocaine or methamphetamine use Minimum of one documented positive urine within 2 weeks of study entry. For those exiting a controlled environment, any stimulant use within two weeks of entering the controlled environment

Exclusion Criteria:

Unable to give informed consent (fails simple consent quiz)
Answers yes to question: Are you in recovery from gambling? That is, have you stopped gambling because of previous gambling problems?

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00033020

Locations


United States, California
	Aegis Medical Systems, Inc.
	Bakersfield, California, United States, 93301 4709

United States, District of Columbia
	Oasis Clinic
	Washington, District of Columbia, United States, 20002

United States, Maryland
	Glenwood Life Counseling Center
	Baltimore, Maryland, United States, 21212

United States, New York
	Lower Eastside Service Center (LESC)
	New York, New York, United States, 10007
	Greenwich House, Inc.
	New York, New York, United States, 10014

United States, Pennsylvania
	ACT
	Philadelphia, Pennsylvania, United States, 19141

United States, South Carolina
	Charleston Center
	Charleston, South Carolina, United States, 29403

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Johns Hopkins University

Investigators


Principal Investigator:	Maxine Stitzer, Ph.D.	Johns Hopkins University

More Information

Data Elements This link exits the ClinicalTrials.gov site

Study ID Numbers:	NIDA-CTN-0007-1
First Received:	April 5, 2002
Last Updated:	July 28, 2008
ClinicalTrials.gov Identifier:	NCT00033020
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Methadone

Mental Disorders

Substance-Related Disorders

Disorders of Environmental Origin

ClinicalTrials.gov processed this record on November 30, 2008